Web based Drug Database (1.07 Linux)

METIPRANOLOL [EYE]

Names
Common Name	METIPRANOLOL [EYE]
Other Name	METIPRANOLOL [EYE]
Pharmacological Group	BETA BLOCKERS
Chemical Name	1-(4-Acetoxy-2,3,5-trimethylphenoxy)-3- isopropylaminopropan-2-ol; 4-(2-Hydroxy-3-isopropylaminopropoxy)-2,3,6-trimethylphenyl acetate
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Open-angle glaucoma
Glaucoma due to pupillary block
Glaucoma due to ocular inflammation
Glaucoma due to ocular trauma

Contraindications

Heart failure
Chronic obstructive airway disease
Asthma
Pulse rate - bradycardia
Complete atrioventricular block
Partial atrioventricular block
Sick sinus syndrome
Raynaud's syndrome
Chronic obstructive pulmonary disease
Chronic asthmatic bronchitis
Cardiogenic shock
Adverse reaction to betablockers
Airways obstruction reversible
Beta blocker contraindicated
Betablocker allergy

Prescriber Cautions

Caution in asthma or other obstructive pulmonary disease

Patient Cautions

See information on products containing METIPRANOLOL [EYE] for specific advice for patients

Toxicity

- None Listed -

Side Effects

Blurred Vision - Common
Bradycardia - Common
Burning or stinging - Common
Hypotension - Common
Anterior uveitis - Uncommon
Bronchospasm - Uncommon
Dyspnoea - Uncommon
Respiratory arrest - Uncommon
Ataxia
Headache
Malaise/lethargy
Muscle weakness
Periorbital oedema
Rash

Liver Disease

Liver disease may alter the response to drugs in several ways. Prescribing should be kept to a minimum in all patients with severe liver disease, especially if jaundice, ascites, or evidence of encephalopathy present

Renal Failure

METIPRANOLOL [EYE] - may reduce renal blood flow and reduce renal function in severe renal failure

Pregnancy

METIPRANOLOL [EYE] may retard intrauterine fetal growth
METIPRANOLOL [EYE] causes neonatal bradycardia related to maternal dose
Avoid METIPRANOLOL [EYE] in the 1st & 2nd TRIMESTER of pregnancy
Risk of neonatal hypoglycaemia with METIPRANOLOL [EYE]

Lactation

Therapeutic doses of METIPRANOLOL [EYE] unlikely to affect infant
METIPRANOLOL [EYE] unlikely to be excreted in milk
Monitor infant
Possible toxicity from METIPRANOLOL [EYE] due to beta-blocker effect

Pharmacological Actions

BETA ANTAGONIST action effect

Diagnostic Procedures

Urine 5-hydroxyindoleacetic acid high
Total bilirubin high
Creatine kinase low
Serum glucose low

Drugs containing METIPRANOLOL [EYE]

MINIMS METIPRANOLOL 0.1% 0.5ml
Metipranolol 0.1% s-d eye dp
METIPRANOLOL 0.1% eye drops
METIPRANOLOL 0.3% eye drops

Interacting Ingredients

ACETOHEXAMIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of ACETOHEXAMIDE. Moderate risk. Monitor
ADRENALINE
Likely interaction of METIPRANOLOL [EYE] increasing the HYPERTENSIVE effect of ADRENALINE. Potential risk. Monitor
ADRENALINE [LOCAL]
Likely interaction of METIPRANOLOL [EYE] increasing the HYPERTENSIVE effect of ADRENALINE [LOCAL]. Potential risk. Monitor
ALFUZOSIN HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOTENSIVE effect of ALFUZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
ALMOTRIPTAN
Infrequent reports of METIPRANOLOL [EYE] increasing the VASOCONSTRICTOR effect of ALMOTRIPTAN. Potential risk. Avoid
AMINOPHYLLINE
Theoretical potential for METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of AMINOPHYLLINE. High risk. Avoid
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. High risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. High risk. Avoid
BETAMETHASONE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. High risk. Avoid
BIPHASIC INSULIN ASPART
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of BIPHASIC INSULIN ASPART. Moderate risk. Monitor
BIPHASIC INSULIN LISPRO
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of BIPHASIC INSULIN LISPRO. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. High risk. Avoid
BUFYLLINE
Theoretical potential for METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of BUFYLLINE. High risk. Avoid
CHLORPROPAMIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of CHLORPROPAMIDE. Moderate risk. Monitor
CHOLINE THEOPHYLLINATE
Theoretical potential for METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. High risk. Avoid
CLONIDINE
Likely interaction of METIPRANOLOL [EYE] increasing the HYPOTENSIVE effect of CLONIDINE. Potential risk. May need to avoid combination
CROMOGLICATE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. High risk. Avoid
DIGITOXIN
Infrequent reports of METIPRANOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of DIGITOXIN. Moderate risk. May need to avoid combination
DIGOXIN
Infrequent reports of METIPRANOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of DIGOXIN. Moderate risk. May need to avoid combination
DIHYDROERGOTAMINE MESILATE
Infrequent reports of DIHYDROERGOTAMINE MESILATE increasing the VASOCONSTRICTOR effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
DILTIAZEM HYDROCHLORIDE
Infrequent reports of DILTIAZEM HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
DIPROPHYLLINE
Theoretical potential for METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of DIPROPHYLLINE. High risk. Avoid
DISOPYRAMIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of DISOPYRAMIDE. Moderate risk. May need to avoid combination
DISTIGMINE
Infrequent reports of DISTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
EDROPHONIUM
Infrequent reports of EDROPHONIUM increasing the NEGATIVE CHRONOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
ELETRIPTAN
Infrequent reports of METIPRANOLOL [EYE] increasing the VASOCONSTRICTOR effect of ELETRIPTAN. Potential risk. Avoid
EPHEDRINE HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. High risk. Avoid
ERGOTAMINE TARTRATE
Infrequent reports of ERGOTAMINE TARTRATE increasing the VASOCONSTRICTOR effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
FELODIPINE
Infrequent reports of FELODIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
FENOTEROL HYDROBROMIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. High risk. Avoid
FLECAINIDE ACETATE
Infrequent reports of METIPRANOLOL [EYE] increasing the BETA ANTAGONIST effect of FLECAINIDE ACETATE. Moderate risk. Monitor
FLUTICASONE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. High risk. Avoid
FORMOTEROL
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of FORMOTEROL. High risk. Avoid
FROVATRIPTAN
Infrequent reports of METIPRANOLOL [EYE] increasing the VASOCONSTRICTOR effect of FROVATRIPTAN. Potential risk. Avoid
GALANTAMINE
Infrequent reports of GALANTAMINE increasing the NEGATIVE CHRONOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
GLIBENCLAMIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIBENCLAMIDE. Moderate risk. Monitor
GLIBORNURIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIBORNURIDE. Moderate risk. Monitor
GLICLAZIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLICLAZIDE. Moderate risk. Monitor
GLIMEPIRIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIMEPIRIDE. Moderate risk. Monitor
GLIPIZIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIPIZIDE. Moderate risk. Monitor
GLIQUIDONE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLIQUIDONE. Moderate risk. Monitor
GLYMIDINE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of GLYMIDINE. Moderate risk. Monitor
HUMAN INSULIN [INHALED]
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of HUMAN INSULIN [INHALED]. Moderate risk. Monitor
INDACATEROL
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of INDACATEROL. High risk. Avoid
INSULIN ASPART
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN ASPART. Moderate risk. Monitor
INSULIN DETEMIR
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN DETEMIR. Moderate risk. Monitor
INSULIN GLARGINE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN GLARGINE. Moderate risk. Monitor
INSULIN GLULISINE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN GLULISINE. Moderate risk. Monitor
INSULIN LISPRO
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of INSULIN LISPRO. Moderate risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. High risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. High risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. High risk. Avoid
ISRADIPINE
Infrequent reports of ISRADIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
KETOTIFEN
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of KETOTIFEN. High risk. Avoid
LACIDIPINE
Infrequent reports of LACIDIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
LERCANIDIPINE
Infrequent reports of LERCANIDIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
MEFLOQUINE HYDROCHLORIDE
Likely interaction of METIPRANOLOL [EYE] increasing the ARRHYTHMOGENIC effect of MEFLOQUINE HYDROCHLORIDE. Moderate risk. May need to avoid combination
METFORMIN HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of METFORMIN HYDROCHLORIDE. Moderate risk. Monitor
METHYSERGIDE
Infrequent reports of METHYSERGIDE increasing the VASOCONSTRICTOR effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
MONTELUKAST
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of MONTELUKAST. High risk. Avoid
MOXISYLYTE
Likely interaction of METIPRANOLOL [EYE] increasing the HYPOTENSIVE effect of MOXISYLYTE. Potential risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. High risk. Avoid
NEOSTIGMINE
Infrequent reports of NEOSTIGMINE increasing the NEGATIVE CHRONOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
NICARDIPINE HYDROCHLORIDE
Infrequent reports of NICARDIPINE HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
NIFEDIPINE
Infrequent reports of NIFEDIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
NIMODIPINE
Infrequent reports of NIMODIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
NISOLDIPINE
Infrequent reports of NISOLDIPINE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
ORCIPRENALINE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of ORCIPRENALINE. High risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. High risk. Avoid
PIRBUTEROL
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of PIRBUTEROL. High risk. Avoid
PIROXICAM
Likely interaction of PIROXICAM reducing the HYPOTENSIVE effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] reducing the HYPOTENSIVE effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX reducing the HYPOTENSIVE effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
PRAZOSIN HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOTENSIVE effect of PRAZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
PRENYLAMINE
Likely interaction of METIPRANOLOL [EYE] increasing the NEGATIVE INOTROPIC effect of PRENYLAMINE. High risk. Monitor
PYRIDOSTIGMINE BROMIDE
Infrequent reports of PYRIDOSTIGMINE BROMIDE increasing the NEGATIVE CHRONOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
QUINIDINE
Infrequent reports of METIPRANOLOL [EYE] increasing the NEGATIVE CHRONOTROPIC effect of QUINIDINE. Moderate risk. May need to avoid combination
REPROTEROL HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. High risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. High risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. High risk. Avoid
SALBUTAMOL
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of SALBUTAMOL. High risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. High risk. Avoid
SALMETEROL XINAFOATE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. High risk. Avoid
SUMATRIPTAN SUCCINATE
Infrequent reports of METIPRANOLOL [EYE] increasing the VASOCONSTRICTOR effect of SUMATRIPTAN SUCCINATE. Potential risk. Avoid
TERAZOSIN HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOTENSIVE effect of TERAZOSIN HYDROCHLORIDE. Potential risk. May need to avoid combination
TERBUTALINE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of TERBUTALINE. High risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. High risk. Avoid
THEOPHYLLINE
Theoretical potential for METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of THEOPHYLLINE. High risk. Avoid
TOLAZAMIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of TOLAZAMIDE. Moderate risk. Monitor
TOLBUTAMIDE
Infrequent reports of METIPRANOLOL [EYE] increasing the HYPOGLYCAEMIC effect of TOLBUTAMIDE. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. High risk. Avoid
VERAPAMIL HYDROCHLORIDE
Infrequent reports of VERAPAMIL HYDROCHLORIDE increasing the NEGATIVE INOTROPIC effect of METIPRANOLOL [EYE]. Moderate risk. Monitor
ZAFIRLUKAST
Infrequent reports of METIPRANOLOL [EYE] reducing the BRONCHODILATOR effect of ZAFIRLUKAST. High risk. Avoid